Breast Cancer

SAN ANTONIO — Levels of a prognostic biomarker for distant metastatic recurrence varied by race among a subset of women who received neoadjuvant chemotherapy, according to study results presented at San Antonio Breast Cancer Symposium.

SAN ANTONIO — Outcomes among women with breast cancer who have similar 21-gene recurrence scores may vary by race, according to study results presented at San Antonio Breast Cancer Symposium.

Jeffrey M. Rosen, PhD, will receive the William L. McGuire Memorial Lecture Award at this year’s San Antonio Breast Cancer Symposium, scheduled for Dec. 6-10.

Contraceptive use significantly decreased 1 year after first-line treatment and at 2-year follow-up among premenopausal women diagnosed with breast cancer, according to study results published in JAMA Network Open.

The FDA granted fast track designation to REM-001 for the treatment of cutaneous metastatic breast cancer.

Proton therapy for partial breast irradiation provided cancer control in 100% of cases of early-stage ER-positive breast cancer, according to 3-year results from a prospective, multicenter phase 2 trial.

The treatment landscape for early-stage triple-negative breast cancer continues to evolve, according to a speaker at Chemotherapy Foundation Symposium.

Deepa R. Halaharvi, DO, was diagnosed with stage I breast cancer just 8 months after starting her career as a breast surgeon. Now, Halaharvi uses her experience to help others who are diagnosed.

An experimental plasmid DNA vaccine produced a strong immune response to the HER2 protein among women with advanced HER2-positive breast cancer, according to results of a single-arm, phase 1 study published in JAMA Oncology.

SAN DIEGO — Higher amounts of visceral and subcutaneous adipose tissue are associated with an increased risk for breast cancer among postmenopausal women, according to a presenter at ObesityWeek 2022.